LifeSci Acquisition Corp.

This is a wind-down vote, not a going-concern warning: LSAC's successor is asking holders to approve liquidation after the alternative merger, conditioned on a $20 million financing, failed to materialize. With trading suspended since April 23, 2025 there is no market exit, so holders are locked into whatever the Plan of Liquidation distributes after creditors. There is no trust account behind a post-de-SPAC shell, so recovery depends entirely on residual cash.

Shares reserved for options, warrants and RSUs total 46.8 million against just 31.4 million outstanding - the potential dilution already exceeds the company itself by half, and a reverse split scales both sides without changing that ratio. A restatement of prior-year stock compensation adds a reporting-quality concern on top. The LifeSci trust was released at the de-SPAC, so nothing supports the shares beneath the sub-dollar price driving the split.

A restatement of stock-based compensation is a control weakness disclosure, not merely a bookkeeping correction: it means the company reported a larger 2022 loss and misstated equity account balances, and the error persisted until identified after the fact. The offsetting point for investors is that the misstatement was non-cash and left reported cash flows unchanged, so liquidity and burn were never overstated. For legacy LifeSci SPAC holders the practical concern is that a company already calling a special meeting is doing so with its historical financials under correction.

An acknowledged accounting error in prior-year stock-based compensation is a control weakness even when, as here, it does not touch cash — it means reported losses and equity balances for 2022 were wrong. For LSAC-legacy holders with no trust to fall back on, that reduces confidence in the reported burn rate. The incentive plan amendment adds shares on top of an already small base at a $5.12 price, so the dilution is real rather than notional.

The earnout is priced far above where the stock sat: three tranches, each worth $20,000,000 divided by the Closing Price Per Share, pay only if the daily volume-weighted average price reaches $20.00 within 42 months, $35.00 within six years and $45.00 within eight years, for 20 trading days in any 30. Against that, the last sale price on the November 20, 2020 record date was $16.40 and the trust held approximately $65.7 million at December 3, 2020. Only 90.6% of any earned Earnout Shares go to the sellers; the rest expands the 2020 Stock Incentive Plan reserve.

The filing states approximately $65.7 million in LSAC's trust account as of October 2, 2020. The earnout is set far above that: three tranches, each equal to $20,000,000 divided by the Closing Price Per Share, triggered only if the daily volume-weighted average price reaches $20.00 within 42 months, $35.00 within six years and $45.00 within eight years, in each case for 20 trading days within any 30 trading-day period. Only 90.6% of any earnout shares earned go to the Sellers; the remainder instead increases the share reserve under the Vincera Pharma, Inc. 2020 Stock Incentive Plan.